Jones Trading将Renovorx升级为2026年1月30日的“Strong-Buy”, 引用其癌症治疗RenovoCathTM中的承诺。 Jones Trading upgraded RenovoRx to "Strong-Buy" on Jan. 30, 2026, citing promise in its cancer therapy RenovoCath™.

Jones Trading RenovoRx(RNXT)于2026年1月30日升级为“Strong-Buy”, 引用其药物破除疗法RenovoCathTM(RenovoCathTM)对于先进的胰腺癌和转移性直肠癌的潜力。 Jones Trading upgraded RenovoRx (RNXT) to "Strong-Buy" on January 30, 2026, citing potential in its drug-device therapy RenovoCath™ for advanced pancreatic and metastatic colorectal cancers. 股价为1.04美元,市场上限为3 812万美元,具有协商一致的“买价”评级,目标价格为7.75美元。 The stock, trading at $1.04 with a $38.12 million market cap, has a consensus "Moderate Buy" rating and a $7.75 target price. 根据估计,该公司报告EPS损失为0.08美元,但收入270 000美元错过了410 000美元的预测。 The company reported a $0.08 EPS loss, in line with estimates, but revenue of $270,000 missed the $410,000 forecast. 分析家预测每股全年损失0.40美元,机构所有权占3.1%。 Analysts project a full-year loss of $0.40 per share, and institutional ownership stands at 3.1%.